PT2495252T - Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah - Google Patents

Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah

Info

Publication number: PT2495252T
Authority: PT; Portugal
Prior art keywords: hendra; glycoprotein; soluble forms; nipah virus; nipah
Prior art date: 2004-07-09

Application number

PT121570717T

Other languages

English (en)

Inventor

C Broder Christopher

N Bossart Katharine

Original Assignee

Henry M Jackson Found Advancement Military Medicine Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-07-09

Filing date

2005-07-07

Publication date

2018-06-22

2005-07-07 Application filed by Henry M Jackson Found Advancement Military Medicine Inc filed Critical Henry M Jackson Found Advancement Military Medicine Inc

2018-06-22 Publication of PT2495252T publication Critical patent/PT2495252T/pt

Links

102000003886 Glycoproteins Human genes 0.000 title 1
108090000288 Glycoproteins Proteins 0.000 title 1
241000893570 Hendra henipavirus Species 0.000 title 1
241000526636 Nipah henipavirus Species 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/065—Poxviridae, e.g. avipoxvirus
- C07K14/07—Vaccinia virus; Variola virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/115—Paramyxoviridae, e.g. parainfluenza virus
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
- C07K16/1027—Paramyxoviridae, e.g. respiratory syncytial virus
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6854—Immunoglobulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
- A61K2039/6031—Proteins
- A61K2039/6075—Viral proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/18011—Paramyxoviridae
- C12N2760/18211—Henipavirus, e.g. hendra virus
- C12N2760/18271—Demonstrated in vivo effect

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Virology (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Immunology (AREA)
Molecular Biology (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
Genetics & Genomics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Microbiology (AREA)
Biomedical Technology (AREA)
Biophysics (AREA)
Hematology (AREA)
Urology & Nephrology (AREA)
Gastroenterology & Hepatology (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Pharmacology & Pharmacy (AREA)
Biotechnology (AREA)
Mycology (AREA)
Epidemiology (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Food Science & Technology (AREA)
Cell Biology (AREA)
Analytical Chemistry (AREA)
Physics & Mathematics (AREA)
Pulmonology (AREA)
Bioinformatics & Cheminformatics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Communicable Diseases (AREA)
Tropical Medicine & Parasitology (AREA)
General Engineering & Computer Science (AREA)
Oncology (AREA)

PT121570717T 2004-07-09 2005-07-07 Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah PT2495252T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US58684304P	2004-07-09	2004-07-09

Publications (1)

Publication Number	Publication Date
PT2495252T true PT2495252T (pt)	2018-06-22

Family

ID=36793510

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
PT121570717T PT2495252T (pt)	2004-07-09	2005-07-07	Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah
PT58575093T PT1789593T (pt)	2004-07-09	2005-07-07	Formas solúveis de glicoproteína g de vírus hendra

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
PT58575093T PT1789593T (pt)	2004-07-09	2005-07-07	Formas solúveis de glicoproteína g de vírus hendra

Country Status (7)

Country	Link
US (7)	US8865171B2 (pt)
EP (3)	EP2495252B1 (pt)
AU (2)	AU2005327194B2 (pt)
ES (2)	ES2622394T3 (pt)
PT (2)	PT2495252T (pt)
TR (1)	TR201808440T4 (pt)
WO (1)	WO2006085979A2 (pt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PT2495252T (pt)	2004-07-09	2018-06-22	Henry M Jackson Found Advancement Military Medicine Inc	Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah
CA2836098C (en) *	2011-05-13	2022-06-21	Zoetis Llc	Hendra and nipah virus g glycoprotein immunogenic compositions
WO2012166450A1 (en) *	2011-05-27	2012-12-06	Merial Limited	Genetic vaccines against hendra virus and nipah virus
MX2016002903A (es) *	2013-09-05	2016-06-06	Zoetis Services Llc	Composiciones inmunogenas de la glicoproteina g de los virus hendra y nipah.
JP2017501162A (ja) *	2013-12-16	2017-01-12	ゾエティス・サービシーズ・エルエルシー	ヘンドラ及びニパウイルスｇ糖タンパク質免疫原性組成物
CN108624602B (zh) *	2017-03-24	2020-10-16	华中农业大学	一株具有阻断活性的抗尼帕病毒g蛋白的单克隆抗体及其应用
JP7370983B2 (ja)	2017-12-20	2023-10-30	ゾエティス・サービシーズ・エルエルシー	ヘンドラウイルス感染症及びニパウイルス感染症に対するワクチン
US11890339B2 (en)	2018-08-03	2024-02-06	The United States of Americam as represented by the Secretary, Department of Health and Human Services	Nipah virus immunogens and their use

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4816567A (en)	1983-04-08	1989-03-28	Genentech, Inc.	Recombinant immunoglobin preparations
US5807715A (en)	1984-08-27	1998-09-15	The Board Of Trustees Of The Leland Stanford Junior University	Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4777127A (en)	1985-09-30	1988-10-11	Labsystems Oy	Human retrovirus-related products and methods of diagnosing and treating conditions associated with said retrovirus
US5219740A (en)	1987-02-13	1993-06-15	Fred Hutchinson Cancer Research Center	Retroviral gene transfer into diploid fibroblasts for gene therapy
US5422120A (en)	1988-05-30	1995-06-06	Depotech Corporation	Heterovesicular liposomes
US5530101A (en)	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
WO1990007936A1 (en)	1989-01-23	1990-07-26	Chiron Corporation	Recombinant therapies for infection and hyperproliferative disorders
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
ES2116269T3 (es)	1989-03-21	1998-07-16	Vical Inc	Expresion de secuencias exogenas de polinucleotidos en un vertebrado.
US6673776B1 (en)	1989-03-21	2004-01-06	Vical Incorporated	Expression of exogenous polynucleotide sequences in a vertebrate, mammal, fish, bird or human
EP0487587A1 (en)	1989-08-18	1992-06-03	Chiron Corporation	Recombinant retroviruses delivering vector constructs to target cells
US5585362A (en)	1989-08-22	1996-12-17	The Regents Of The University Of Michigan	Adenovirus vectors for gene therapy
NZ237464A (en)	1990-03-21	1995-02-24	Depotech Corp	Liposomes with at least two separate chambers encapsulating two separate biologically active substances
US5427908A (en)	1990-05-01	1995-06-27	Affymax Technologies N.V.	Recombinant library screening methods
DE69233013T2 (de)	1991-08-20	2004-03-04	The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer	Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
AU669124B2 (en)	1991-09-18	1996-05-30	Kyowa Hakko Kirin Co., Ltd.	Process for producing humanized chimera antibody
ES2136092T3 (es)	1991-09-23	1999-11-16	Medical Res Council	Procedimientos para la produccion de anticuerpos humanizados.
WO1993010218A1 (en)	1991-11-14	1993-05-27	The United States Government As Represented By The Secretary Of The Department Of Health And Human Services	Vectors including foreign genes and negative selective markers
GB9125623D0 (en)	1991-12-02	1992-01-29	Dynal As	Cell modification
FR2688514A1 (fr)	1992-03-16	1993-09-17	Centre Nat Rech Scient	Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
US5733743A (en)	1992-03-24	1998-03-31	Cambridge Antibody Technology Limited	Methods for producing members of specific binding pairs
JPH07507689A (ja)	1992-06-08	1995-08-31	ザリージェンツオブザユニバーシティオブカリフォルニア	特定組織のターゲティング方法及び組成物
JPH09507741A (ja)	1992-06-10	1997-08-12	アメリカ合衆国	ヒト血清による不活性化に耐性のあるベクター粒子
GB2269175A (en)	1992-07-31	1994-02-02	Imperial College	Retroviral vectors
EP0673431A1 (en)	1992-12-03	1995-09-27	Genzyme Corporation	Gene therapy for cystic fibrosis
PT695169E (pt)	1993-04-22	2003-04-30	Skyepharma Inc	Lipossomas multivesiculares de ciclodextrina encapsulando compostos farmacologicos e metodos para a sua utilizacao
ATE304604T1 (de)	1993-06-24	2005-09-15	Frank L Graham	Adenovirus vektoren für gentherapie
US6015686A (en)	1993-09-15	2000-01-18	Chiron Viagene, Inc.	Eukaryotic layered vector initiation systems
EP0716148B1 (en)	1993-09-15	2004-01-02	Chiron Corporation	Recombinant alphavirus vectors
BR9407956A (pt)	1993-10-25	1996-11-26	Canji Inc	Composiçao farmacêutica vetor de express o de adenovirus recombinante e kit par reduzir a proliferaçao de células tumorais
RU2160093C2 (ru)	1993-11-16	2000-12-10	Скайефарма Инк.	Везикулы с регулируемым высвобождением активных ингредиентов
US6436908B1 (en)	1995-05-30	2002-08-20	Duke University	Use of exogenous β-adrenergic receptor and β-adrenergic receptor kinase gene constructs to enhance myocardial function
AU2585395A (en)	1994-05-09	1995-11-29	Chiron Corporation	Retroviral vectors having a reduced recombination rate
AU4594996A (en)	1994-11-30	1996-06-19	Chiron Viagene, Inc.	Recombinant alphavirus vectors
US6265150B1 (en)	1995-06-07	2001-07-24	Becton Dickinson & Company	Phage antibodies
ATE424463T1 (de)	1996-05-06	2009-03-15	Oxford Biomedica Ltd	Rekombinationsunfähige retrovirale vektoren
US6376471B1 (en)	1997-10-10	2002-04-23	Johns Hopkins University	Gene delivery compositions and methods
WO2005028673A1 (en) *	2003-09-22	2005-03-31	Institut Pasteur	A method for detecting nipah virus and method for providing immunoprotection against henipaviruses
PT2495252T (pt)	2004-07-09	2018-06-22	Henry M Jackson Found Advancement Military Medicine Inc	Formas solúveis de glicoproteína g de vírus hendra e de vírus nipah
US7988971B2 (en) *	2005-03-14	2011-08-02	The United States Of America As Represented By The Department Of Health And Human Services	Human monoclonal antibodies against Hendra and Nipah viruses
WO2007005244A1 (en) *	2005-07-05	2007-01-11	The Regents Of The University Of California	Henipavirus receptor and uses thereof

2005
- 2005-07-07 PT PT121570717T patent/PT2495252T/pt unknown
- 2005-07-07 PT PT58575093T patent/PT1789593T/pt unknown
- 2005-07-07 US US11/629,682 patent/US8865171B2/en active Active
- 2005-07-07 EP EP12157071.7A patent/EP2495252B1/en active Active
- 2005-07-07 TR TR2018/08440T patent/TR201808440T4/tr unknown
- 2005-07-07 EP EP05857509.3A patent/EP1789593B1/en active Active
- 2005-07-07 EP EP18160722.7A patent/EP3381930A1/en active Pending
- 2005-07-07 ES ES05857509.3T patent/ES2622394T3/es active Active
- 2005-07-07 ES ES12157071.7T patent/ES2673972T3/es active Active
- 2005-07-07 AU AU2005327194A patent/AU2005327194B2/en active Active
- 2005-07-07 WO PCT/US2005/024022 patent/WO2006085979A2/en active Application Filing
2010
- 2010-11-11 AU AU2010241382A patent/AU2010241382B2/en active Active
2012
- 2012-06-22 US US13/530,922 patent/US9045532B2/en active Active
- 2012-06-22 US US13/530,866 patent/US9056902B2/en active Active
2015
- 2015-04-30 US US14/701,006 patent/US9533038B2/en active Active
2016
- 2016-12-30 US US15/395,418 patent/US10053495B2/en active Active
2018
- 2018-07-25 US US16/044,985 patent/US20190031719A1/en not_active Abandoned
2021
- 2021-01-29 US US17/161,720 patent/US20210230230A1/en active Pending

Also Published As

Publication number	Publication date
US20170174728A1 (en)	2017-06-22
US9056902B2 (en)	2015-06-16
AU2010241382A1 (en)	2010-12-02
AU2005327194B2 (en)	2010-09-09
US20130171131A1 (en)	2013-07-04
US10053495B2 (en)	2018-08-21
AU2005327194A1 (en)	2006-08-17
US20090041772A1 (en)	2009-02-12
EP1789593B1 (en)	2017-03-15
ES2622394T3 (es)	2017-07-06
WO2006085979A2 (en)	2006-08-17
EP2495252A2 (en)	2012-09-05
US20150306208A1 (en)	2015-10-29
EP1789593A2 (en)	2007-05-30
US20190031719A1 (en)	2019-01-31
EP1789593A4 (en)	2009-12-23
EP2495252B1 (en)	2018-04-18
WO2006085979A3 (en)	2009-04-09
EP3381930A1 (en)	2018-10-03
EP2495252A3 (en)	2013-05-01
US9533038B2 (en)	2017-01-03
PT1789593T (pt)	2017-04-24
US8865171B2 (en)	2014-10-21
US20130171132A1 (en)	2013-07-04
ES2673972T3 (es)	2018-06-26
US20210230230A1 (en)	2021-07-29
TR201808440T4 (tr)	2018-07-23
US9045532B2 (en)	2015-06-02
AU2010241382B2 (en)	2012-10-11
WO2006085979A9 (en)	2009-08-13

Publication	Publication Date	Title
EP1789593A4 (en)	2009-12-23	SOLUBLE FORMS OF HENDRA AND NIPAH VIRUS G-GLYCOPROTEIN
CR8037A (es)	2008-07-29	Derivados de 2- acilamino- 4- feniletiazol, su preparacion y su aplicacion en terapeutica
IL196552A0 (en)	2009-11-18	Separation and contrast enhancement of overlapping cast shadow components and target detection in shadow using polarization
IL183888A0 (en)	2007-10-31	Rescue of influenza virus
IS7426A (is)	2004-09-15	Veirulíkar agnir af mennskri vörtuveiru
EP1726660A4 (en)	2009-08-05	METHOD OF MEASURING GLYCOPROTEINS
EP1817308A4 (en)	2007-12-26	CYCLOPAMINE ANALOGS AND METHODS OF USE THEREOF
IL177650A0 (en)	2006-12-31	Isoquinoline derivatives and methods of use thereof
HK1117519A1 (en)	2009-01-16	Substituted benzimidazoles and methods of preparation
DK1922309T3 (da)	2014-08-25	N-phenyl-2-pyrimidin-aminderivater og fremgangsmåde til fremstillingen deraf
HK1101347A1 (en)	2007-10-18	Fasudil-containing preparation and method of improving stability thereof
EP1940460A4 (en)	2009-08-12	OLIGOD DRO CYTEN MYELIN GLYCOPROTEIN COMPOSITIONS AND USES THEREOF
IL195244A0 (en)	2009-09-22	Inhibitors of human immunodeficiency virus replication
EP1937298A4 (en)	2009-11-11	USE OF LACTOFERRIN FRAGMENTS AND HYDROLYSATES
EP1827391A4 (en)	2010-03-17	DOSAGE FORMS AND METHODS OF USE THEREOF
IL188766A0 (en)	2008-08-07	Methods for reducing viral load in hiv-1 infected patients
EP1773880A4 (en)	2009-09-09	ENV POLYPEPTIDE COMPLEXES AND METHOD FOR THEIR USE
HK1106229A1 (en)	2008-03-07	Tetrahydroisoquinoline sulfonamide derivatives, the preparation thereof, and the use of the same in therapeutics
EP2227483A4 (en)	2011-12-28	SOLUBLE FORMS OF HENDRA AND NIPAH VIRUS F-GLYCOPROTEIN AND APPLICATIONS THEREOF
EP1766092A4 (en)	2009-10-28	TARGET-SPECIFIC COMPOMERS AND METHOD OF USE
EP1946007A4 (en)	2011-08-17	ANDROSTERONE DERIVATIVES AND METHODS OF USE
EP2451979A4 (en)	2013-03-13	METHOD FOR DETECTING HUMAN IMMUNODEFICIENCY VIRUS TYPE 1 (HIV-1) AND KIT FOR IMPLEMENTING SAID METHOD
EP1833989A4 (en)	2009-01-21	VIRUS PREPARATIONS AND METHODS
EP1893778A4 (en)	2010-05-05	PROOF OF HIV-1 INFECTION
EP1776140A4 (en)	2010-09-08	METHOD FOR INHIBITING VIRAL REPLICATION